- Clinical-stage biopharmaceutical company InflaRx N.V. (NASDAQ:IFRX) appoints Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.
- Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry.
- She will be responsible for all clinical developments related to InflaRx’s portfolio as she joins the C-suite of the company.